Chronic Hepatitis B Infection: Patient Guidance
This patient guidance document is intended for all people at risk of or living with chronic hepatitis B (CHB) infection. Globally, CHB is one of the leading causes of cirrhosis and hepatocellular carcinoma, the most common form of liver cancer. However, less than one in five infected individuals is aware of their condition and only a small fraction of these individuals receive proper assessment and management. Safe and effective treatment is available in many countries and regions and is recommended for infected individuals who have evidence of liver damage or are at risk of complications. Several essential measures are advised for all people living with CHB, including lifestyle habits, screening for coinfection, managing comorbidities, fibrosis assessment, preventing HBV transmission, and surveillance for liver cancer. There are also recent shifts in the treatment paradigm and novel drug development. In those living with CHB, a better understanding of the disease can empower them to play an active role in management in partnership with their physicians. This guidance document has been developed in collaboration with clinicians, scientists, patients, and patient representatives to summarize updated salient knowledge to inform people at risk of or living with CHB.
Authors
- Ruveena Bhavani Rajaram (ORCID: https://orcid.org/0000-0002-3855-6536)
- Sakkarin Chirapongsathorn (ORCID: https://orcid.org/0000-0001-6924-8504)
- Nobuharu Tamaki (ORCID: https://orcid.org/0000-0003-4634-6616)
- Rashid Nok-Shun Lui (ORCID: https://orcid.org/0000-0003-1277-9595)
- Yao‐Chun Hsu (ORCID: https://orcid.org/0000-0001-8984-5103)
- Madhumita Premkumar (ORCID: https://orcid.org/0000-0003-2961-4148)
- Anand Vijay Kulkarni (ORCID: https://orcid.org/0000-0002-1240-1675)
- Lung‐Yi Mak (ORCID: https://orcid.org/0000-0002-2266-3935)
- Jimmy Che‐To Lai (ORCID: https://orcid.org/0000-0002-5749-1598)
- Cosmas Rinaldi Adithya Lesmana (ORCID: https://orcid.org/0000-0001-9992-9968)
- Grace Lai–Hung Wong (ORCID: https://orcid.org/0000-0002-2863-9389)
- Kuo Chao Yew (ORCID: https://orcid.org/0000-0003-2005-675X)
- Mara Teresa Panlilio (ORCID: https://orcid.org/0009-0003-4649-7366)
- Liang Shen (ORCID: https://orcid.org/0000-0002-2199-9090)
- Hye Won Lee (ORCID: https://orcid.org/0000-0002-3552-3560)
- Ken Liu (ORCID: https://orcid.org/0000-0002-0453-3168)
- Dongdong Huang (ORCID: https://orcid.org/0009-0006-6408-0910)
- Dorothy Cheung
Institutions
- The University of Sydney (AU)
- University Malaya Medical Centre (MY)
- National University of Singapore (SG)
- Chinese University of Hong Kong (HK)
- Yonsei University (KR)
- Philippine General Hospital (PH)
- Tan Tock Seng Hospital (SG)
- University of Malaya (MY)
- Phramongkutklao Hospital (TH)
- E-Da Hospital (TW)
- Asian Institute of Gastroenterology (IN)
- National University Hospital (SG)
- Musashino Red Cross Hospital (JP)
- Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo (ID)
- The Patients Association (GB)
- Post Graduate Institute of Medical Education and Research (IN)
- University of Hong Kong (HK)
- I-Shou University (TW)
Publication Details
- Journal
- Journal of Gastroenterology and Hepatology
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1111/jgh.70177
- Citations
- 1
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Gilead Sciences
- Kowa Company